This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Scientists discover two cellular defects appear to drive disease in lupus

T cell
Credit: Pixabay/CC0 Public Domain

Northwestern Medicine and Brigham and Women's Hospital scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect may potentially reverse the disease.

Lupus affects more than 1.5 million people in the U.S. Until this new study, the causes of this disease were unclear. Lupus can result in life-threatening damage to multiple organs including the kidneys, brain and heart. Existing treatments often fail to control the disease, the study authors said, and have unintended side effects of reducing the immune system's ability to fight infections.

"Up until this point, all therapy for lupus is a blunt instrument. It's broad immunosuppression," said co-corresponding author Dr. Jaehyuk Choi, associate professor of dermatology at Northwestern University Feinberg School of Medicine and a Northwestern Medicine dermatologist. "By identifying a cause for this disease, we have found a potential cure that will not have the side effects of current therapies."

"We've identified a fundamental imbalance in the immune responses that patients with lupus make, and we've defined specific mediators that can correct this imbalance to dampen the pathologic autoimmune response," said co-corresponding author Dr. Deepak Rao, an assistant professor of medicine at Harvard Medical School and a rheumatologist at Brigham and Women's Hospital and co-director of its Center for Cellular Profiling.

In a study published in Nature on July 10, the scientists report a new pathway that drives disease in lupus. The title of the article is "Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus."

There are disease-associated changes in multiple molecules in the blood of patients with lupus. Ultimately, these changes lead to insufficient activation of a pathway controlled by the aryl hydrocarbon receptor (AHR), which regulates cells' response to environmental pollutants, bacteria or metabolites.

Insufficient activation of AHR results in too many disease-promoting , called the T peripheral helper cells, that promote the production of disease-causing autoantibodies.

To show this discovery can be leveraged for treatments, the investigators returned the aryl hydrocarbon receptor-activating molecules to blood samples from lupus patients. This seemed to reprogram these lupus-causing cells into a cell called a Th22 cell that may promote wound healing from the damage caused by this autoimmune disease.

"We found that if we either activate the AHR pathway with small molecule activators or limit the pathologically excessive interferon in the blood, we can reduce the number of these disease-causing cells," said Choi, also the Jack W. Graffin Professor at Feinberg. "If these effects are durable, this may be a potential cure."

Choi, Rao and colleagues next want to expand their efforts into developing novel treatments for lupus patients. They are now working to find ways to deliver these molecules safely and effectively to people.

More information: Deepak Rao, Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus, Nature (2024). DOI: 10.1038/s41586-024-07627-2.

Journal information: Nature
Citation: Scientists discover two cellular defects appear to drive disease in lupus (2024, July 10) retrieved 23 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Air pollution may affect lupus risk


Feedback to editors